||Researchers at the University
of Pennsylvania School of Medicine recently identified
how a regulatory protein called Bcl-3 helps to control
the body’s inflammation response to infection by
interfering a critical biochemical process called ubiquitination.
||Ubiquitination is an intracellular system
of checks and balances, where cellular proteins are flagged
for disposal. During exposure to infection, Bcl-3 appears
to overrule the p50 ubiquitination, stabilizing the presence
of p50 on DNA and halting inflammation.
||The paper was recently published
(PHILADELPHIA) – Researchers at the University
of Pennsylvania School of Medicine recently identified how a regulatory protein called Bcl-3 helps to control the body’s inflammation response
to infection by interfering a critical biochemical process called
ubiquitination. While previous studies suggested Bcl-3 plays a
role in immunity, this is the first report that Bcl-3 regulates
inflammation by blocking ubiquitination.
Their findings, published in Science, open new avenues of exploration
for developing therapies to treat infectious or inflammatory diseases,
such as sepsis, diabetes, and rheumatoid
“The novelty of our study is the discovery that Bcl-3 acting on
gene expression has a profound effect on inflammation,” says Ruaidhri
Carmody, PhD, Senior Research Investigator in the Department
of Pathology and Laboratory Medicine and first author of the Science paper. “By
mimicking Bcl-3 activity, we may be able to create an artificial
way to block the inflammatory response.”
In the laboratory of senior author Youhai Chen,
PhD, Associate Professor
of Pathology and Laboratory Medicine, Carmody and others searched for
clues as to how Bcl-3 controls inflammation by examining how Bcl-3-deficient
mouse cells respond to infection. Their studies revealed that Bcl-3 interacts
with p50, a protein that inhibits gene transcription by binding to DNA.
“p50 turns off the DNA region coding for inflammation, halting
the response to infection,” explains Chen. Without Bcl-3, Chen
says p50 cannot stop the inflammation response, but instead will become
degraded very fast, through ubiquintination.
Ubiquitination is an intracellular system of checks and balances, where
cellular proteins are flagged for disposal. During exposure to infection,
Bcl-3 appears to overrule the p50 ubiquitination, stabilizing the presence
of p50 on DNA and halting inflammation.
“Our study identifies another layer of information that controls
the inflammatory response,” says Chen. “Bcl-3 appears to
take in information from the body and, in response to infection, interferes
with p50 degradation to decrease inflammatory response.”
“Inflammation is natural,” says Chen. “If we didn’t
respond to infectious agents, bacteria would kill us. However, the inflammatory
response must be controlled or we could also die. Bcl-3 helps regulate
“By using what we now know about Bcl-3 regulatory function, we
hope to create new ways to control inflammation for therapeutic purposes
with selective anti-inflammatory agents,” says Carmody.
Although drugs to suppress inflammation currently exist, Chen and Carmody
say they cause many undesirable side effects in patients with inflammatory
“Current drug treatments target inflammation signaling pathways.
When you inhibit entire pathways, you can produce negative side effects,” said
Carmody. “Since Bcl-3 acts on specific genes, we should be able
to target a subset of dangerous regulatory genes without disrupting other
important immune responses.” Such drugs could benefit patients
with chronic inflammation and transplant recipients as well as those
suffering with inflammatory diseases.
In the future, the scientists aim to determine the components of the
cell responsible for flagging p50 for destruction and instructing Bcl-3
to perform its vital function.
Penn co-authors are Qingguo
Ruan, Scott Palmer, and Brendan Hilliard.
This research was funded by the National
Institute of Allergy and Infectious Diseases.
PENN Medicine is
a $3.5 billion enterprise dedicated to the related missions
of medical education, biomedical research, and excellence in
patient care. PENN Medicine consists of the University of Pennsylvania
School of Medicine (founded in 1765 as the nation's first medical
school) and the University of Pennsylvania Health System.
Penn's School of Medicine is currently ranked #3 in the
nation in U.S.News & World Report's survey of top research-oriented
medical schools; and, according to most recent data from the
National Institutes of Health, received over $379 million in
NIH research funds in the 2006 fiscal year. Supporting 1,400
fulltime faculty and 700 students, the School of Medicine is
recognized worldwide for its superior education and training
of the next generation of physician-scientists and leaders of
The University of Pennsylvania Health System includes
three hospitals — its flagship hospital,
the Hospital of the University of Pennsylvania, rated one of
the nation’s “Honor Roll” hospitals by U.S.News & World
Report; Pennsylvania Hospital, the nation's first hospital; and
Penn Presbyterian Medical Center — a
faculty practice plan; a primary-care provider network; two multispecialty
satellite facilities; and home care and hospice.